Q4 2019: Stable performance and increased profitability
Significant events in the fourth quarter · Net sales rose 2% during the quarter to MSEK 166 (unchanged incl. adjustments for currency effects), which was in line with the company’s expectations. Full-year net sales increased 4% to MSEK 626 (MSEK 605 incl. adjustments for currency effects). · Profitability improved and the EBITDA margin was 29% for full-year 2019 (27% adjusted for IFRS 16), compared with 26% in the preceding year. · Two exclusive supply agreements were signed with major customers in the US. · The Lancet Rheumatology published findings from the company’s